BL-B01D1 is a bispecific ADC that targets EGFR and HER3 through the bispecific antibody Izalontamab and inhibits DNA replication and DNA synthesis through its ADC toxin ED04, exhibiting cytotoxicity against various cancer cells.

Physicochemical Properties

Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911.

Solubility Data